ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 155 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 2.37 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,924 | +121.9% | 978 | +325.2% | 0.00% | – |
| Q2 2023 | $4,922 | +220.2% | 230 | +505.3% | 0.00% | – |
| Q1 2023 | $1,537 | -66.3% | 38 | -61.2% | 0.00% | – |
| Q4 2022 | $4,559 | -54.4% | 98 | -48.7% | 0.00% | – |
| Q3 2022 | $10,000 | +25.0% | 191 | +15.1% | 0.00% | – |
| Q2 2022 | $8,000 | -71.4% | 166 | -57.7% | 0.00% | -100.0% |
| Q1 2022 | $28,000 | +75.0% | 392 | +86.7% | 0.00% | – |
| Q4 2021 | $16,000 | +33.3% | 210 | +2.4% | 0.00% | – |
| Q3 2021 | $12,000 | +20.0% | 205 | -6.4% | 0.00% | – |
| Q2 2021 | $10,000 | +42.9% | 219 | +47.0% | 0.00% | – |
| Q1 2021 | $7,000 | +40.0% | 149 | +38.0% | 0.00% | – |
| Q4 2020 | $5,000 | -70.6% | 108 | -70.4% | 0.00% | -100.0% |
| Q3 2020 | $17,000 | +88.9% | 365 | +108.6% | 0.00% | 0.0% |
| Q2 2020 | $9,000 | +80.0% | 175 | +90.2% | 0.00% | – |
| Q1 2020 | $5,000 | – | 92 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |